title: Design and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertension.
abstract: This article describes the design and methodology of the POWER study (Physicians' Observational Work on Patient Education According to their Vascular Risk). POWER is an open-label multinational postmarketing study of the angiotensin II-receptor blocker eprosartan. The Systemic Coronary Risk Evaluation (SCORE) model has been used to estimate total cardiovascular risk and changes in total cardiovascular risk status during treatment for patients recruited in all countries other than Canada. Framingham Heart Study equations have been used to estimate risk in the Canadian contingent of POWER. Observations from POWER will provide insights into how clinicians try to achieve blood pressure goals within the framework of total cardiovascular risk management and how they integrate their treatment of blood pressure with other interventions. Experience during the POWER study may also help to affirm the utility, practicability and perhaps limitations of the SCORE system for estimating total cardiovascular risk and identify ways to improve the acceptance and implementation of risk estimation methods in cardiovascular primary prevention.
authors: Department of Public Health, Ghent University, Ghent, Belgium. guy.debacker@ugent.be
authors: Guy
authors: G
authors: De Backer
authors: Robert J
authors: RJ
authors: Petrella
authors: Assen R
authors: AR
authors: Goudev
authors: Ghazi A
authors: GA
authors: Radaideh
authors: Andrzej
authors: A
authors: Rynkiewicz
authors: Atul
authors: A
authors: Pathak
mesh_terms: D000179:Acrylates / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001795:Blood Pressure Determination / Q000379:methods; D002170:Canada; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use; D011320:Primary Health Care / Q000379:methods*; D011358:Product Surveillance, Postmarketing; D012107:Research Design; D012307:Risk Factors; D013876:Thiophenes / Q000627:therapeutic use
chemical_list: D000179:Acrylates; D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan